Doximity, Inc. (DOCS) Stock Price & Analysis

Doximity, Inc. (DOCS) closed at USD 33.68 on Thursday, October 22, 2026, up 0.30% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 33.58; the Oct 22, 2026 session ranged USD 33.37–34.15 on volume of 2,846,455 shares. Market capitalization is $6.00B, with a 52-week range of USD 17.15–71.37 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.

Also available as compact Markdown for AI agents: nexqual.com/DOCS.md

Key facts (DOCS)

• Last four reported quarters (through Jun 30, 2026): revenue $656M, net income $167M (25.5% margin) (SEC filings).
• Valuation: P/E 35.9x (avg 37.8x at the last 3 fiscal year-ends).
• 1 of 80 tracked superinvestors hold DOCS (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
• Insider open-market sales, last ~7 months: 13 Form 4 filings, $1.1M; 0 not under a Rule 10b5-1 plan ($0K); 1 by opportunistic insiders (0 outside 10b5-1 plans), 4 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 2.52 on a 1–5 scale) (21 analysts), mean target USD 31.11 (range 18–47).
• Total return with dividends: 1Y -49.2% vs S&P 500 +14.9%; 5Y -48.0% vs S&P 500 +80.3%.
• Next earnings: 2026-11-05, EPS estimate USD 0.35, revenue estimate $170M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DOCS)

Fiscal years end Mar. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (DOCS)

P/E 35.9x · P/S 9.2x · P/B 6.5x · Earnings yield 2.78% · Buyback yield (TTM) 6.68%

P/E at fiscal year-ends: Mar 2026 23.7x, Mar 2025 52.3x, Mar 2024 37.5x.

Superinvestors (SEC 13F-HR, Q2 2026) (DOCS)

1 of 80 tracked investors hold DOCS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (DOCS)

13 of 13 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (DOCS)

Consensus Hold (mean 2.52 on a 1–5 scale), 21 analysts; mean target USD 31.11 (low 18, high 47).

Rating changes, last 120 days:

Total return (dividends reinvested) (DOCS)

DOCS revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

DOCS suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed May 19, 2026.

DOCS customer concentration

In the period ended Mar 31, 2026, a single direct customer accounted for 11% of revenue, per the company's 10-K filed May 19, 2026. The company does not name it.

DOCS company outlook (results filed Aug 6, 2026)

• “Doximity is providing guidance for its fiscal second quarter ending September 30, 2026 as follows: • Revenue between $170 million and $171 million. • Adjusted EBITDA between $80.5 million and $81.5 million.”
• “Doximity is updating guidance for its fiscal year ending March 31, 2027 as follows: • Revenue between $671 million and $681 million. • Adjusted EBITDA between $309 million and $329 million.”

Analysts expect $170.3M for the current quarter, in line with the midpoint of the company's guidance ($170.5M).

Quoted word-for-word from the SEC 8-K results press release.

DOCS analyst estimates and revisions

Key Statistics (as of October 23, 2026 at 09:23 UTC)

Technical Analysis (DOCS)

Nexqual's technical model rates DOCS "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.

Analyst Ratings (DOCS)

Wall Street analysts rate DOCS "Hold" based on 21 analysts, with a mean price target of USD 31.11 (range USD 18–47), per Nexqual as of October 23, 2026 at 09:23 UTC.

Earnings (DOCS)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Financials & Fundamentals (DOCS)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Ownership (DOCS)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Leadership (DOCS)

Doximity, Inc. is led by Jeffrey A. Tangney, Co-Founder, CEO & Chairperson, per Nexqual as of October 23, 2026 at 09:23 UTC.

Major Backers & Investors (DOCS)

Notable institutional backers of Doximity, Inc. include Shaw D.E. & Co., Inc., Two Sigma Investments, LP, Goldman Sachs, according to Nexqual as of October 23, 2026 at 09:23 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

From Doximity, Inc.'s Latest SEC 10-K Filing (filed 2026-05-19)

Key Strengths & Strategy (as disclosed to the SEC)

• We are the leading physician-first tech company, with over 3 million registered members1 as of March 31, 2026.
• Once verified, members gain access to our network, newsfeed, and—depending on their credentials—our Clinical AI Suite, including Dialer, our voice and video telehealth product; Scribe, our ambient AI that listens during patient visits and generates structured notes; and Ask (formerly DoxGPT), which provides evidence-based answers to clinical questions, including drug information.
• The product is HIPAA-compliant for all users, with data encrypted in transit and at rest.
• For example, the laws of the State of California, in which we operate, are more restrictive than HIPAA, including the provisions of the California Consumer Privacy Act and the California Privacy Act.

Partnerships

• Patients can search for the right doctor or hospital for their needs through our collaboration with the Doctor Finder tool of U.S.
• Sponsored content is developed in collaboration with our customer success team to ensure they meet the high-quality standards of our community.

Legal & Regulatory Risks (Item 1A, quoted)

• We may become, and are subject to, litigation, which could have a material adverse effect on our business, financial condition, and results of operations.
• Our development, deployment, and use of artificial intelligence (AI) may not achieve the expected benefits and may create operational, reputational, competitive, regulatory, legal, and liability risks.
• We are subject to stringent and changing laws, regulations, self-regulatory schemes, contractual obligations, and standards related to privacy, data protection, and information security. The actual or perceived failure by us, our customers, partners, or vendors to comply with such obligations could harm our reputation, subject us to significant fines and liability, or otherwise adversely affect our business.
• We may become subject to enforcement actions or litigation as a result of our or our members' failure to comply with laws and regulations relating to communications, even though noncompliance was inadvertent or unintentional.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt